ÂÜÀòÂÒÂ×

Peiwen Yu has a strong background in the pharmaceutical industry with significant experience in various leadership roles. Beginning in 1996, Yu worked at Roche as a Research Scientist before moving on to Rigel as a Scientist from 1998 to 2001. Yu then joined Exelixis in 2001, where they held positions as a Scientist II, Senior Scientist, and Associate Director in Molecular Pharmacology.

In 2006, Yu became a Director and later a Senior Director in Molecular and Cellular Pharmacology at Exelixis. From 2010 to 2013, Yu served as the Senior Director and Department Head in Molecular and Cellular Pharmacology at Exelixis. Yu also held the role of Senior Director in Medical Affairs from 2012 to 2014 at Exelixis.

In 2015, Yu joined OBI Pharma, Inc as the VP of Translational Research, where they created a Translational Science department and implemented project management strategies for the in-house research pipeline.

Yu returned to Exelixis in 2017 and held the positions of VP and Head of Discovery Sciences & Technologies and VP of Discovery Biology. In these roles, Yu was responsible for leading and managing large teams, overseeing various research and development activities, and spearheading important clinical trials for new therapies.

Most recently, Yu joined Initial Therapeutics in 2023 as the SVP of Discovery Biology.

Peiwen Yu obtained a Ph.D. in Immunology/Cell biology from the University of Wisconsin-Madison, where they studied from 1991 to 1996. Prior to that, Peiwen Yu completed a Bachelor's and Master's degree in an unspecified field of study at National Taiwan University. However, the specific duration of their studies at National Taiwan University is not provided.